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It is just over two decades since a small start-up firm called University Diagnostics launched a 
mail-order genetic testing service in the UK in 1996. That same year, the US-based Genetics and 
IVF Institute began marketing its BRCA tests for breast and ovarian cancer directly to 
consumers via newspaper ads. Two years later, Myriad Genetics (by then the sole provider of 
BRCA testing in the USA) launched a consumer advertising campaign that encompassed TV, 
radio and popular magazines (Parthasarathy 2007). By 2001, when UK nutrigenetics firm 
Sciona began marketing to consumers via its website, a new trend was emerging: the growth of 
the direct-to-consumer genetic testing (DTCGT) market was now interlinked with the increasing 
use of the internet as a medium for retail shopping. Genetics was beginning to move out of the 
clinic and into the marketplace. 
Despite little evidence of significant consumer uptake, the consumerisation of genomics has 
garnered extensive media coverage, provoked much public controversy and stimulated 
considerable academic research. Some twenty years since its inception, and a decade since the 
second wave of DTCGT firms launched, this is an opportune moment to take stock of the past, 
present and future of what remains a market in the making. The articles that follow tackle a 
variety of topics: regulation, rhetoric, venture capital financing, and the attitudes of consumers 
and healthcare professionals. The contributions situate DTCGT firms in their historical and 
geographical contexts, highlighting continuities between generations of firms and critically 
evaluating how claims to innovation, novelty and disruption are used to legitimate their 
practices.1 
DTCGT in a historical perspective 
Since 1996, there have been two main waves of DCGT firms: before 2005, the first wave of firms, 
such as Sciona, largely focused on nutrigenetic testing, testing for genes linked to nutrient 
metabolism and providing tailored dietary recommendations; from around 2007, a second wave 
of larger firms, such as Navigenics and 23andMe, began offering polygenic risk tests for a range 
of common diseases such as asthma, diabetes and stroke as they sought to capitalise on gene-
disease associations emerging from the new wave of large-scale Genome-Wide Association 
                                                          
1 Some terminological clarity is required. The term “direct-to-consumer” has been used describe 
two distinct models: firstly, where a firm advertises direct to the public, but the test must still be 
ordered by (and the results delivered to) a healthcare professional; and secondly, the more 
common model where a consumer buys directly from a firm, without the involvement of the 
consumer’s healthcare provider (in some instances the test may, in strict legal terms, be 
“ordered” by a healthcare professional employed by the firm solely for this purpose, but this 
does not establish a doctor-patient relationship with the consumer). 
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Studies (GWAS). Navigenics and 23andMe were better capitalised than their predecessors in the 
DTCGT market (see Hogarth this issue), and both firms had links to highly-respected DNA chip 
makers (Affymetrix and Illumina respectively), which were looking to shift from the biomedical 
research market to the clinical market; and collaborative partnerships with global software 
firms (Microsoft and Google respectively), which were interested in DNA as big data (see 
Saukko this issue) and the opportunities in the burgeoning electronic healthcare records 
market.  
In the last decade the DTCGT market appears to have grown further, at least in terms of the 
number of firms that have entered the market: Philips’ (2016) survey identified 246 firms. The 
heterogeneity of product offerings has also expanded: DTCGT firms specialise in different areas 
such as ancestry, athletic traits, character/personality, familial relatedness, nutrigenetics, and 
quirky traits such as a propensity towards ear wax. Health-related testing covers a diverse 
range of tests including carrier testing for genetic diseases; polygenic susceptibility tests; and 
pharmacogenetic tests that seek to guide drug dosage decisions. The lexicon of terms these 
firms use to describe their services has also expanded: terms like recreational genomics, 
informational genomics and lifestyle genomics may demonstrate a diversity of product 
differentiation strategies, but they also perform boundary work, distancing DTCGT firms from 
the clinical domain (Saukko, Reed, Britten and Hogarth 2010) and functioning as a form of 
regulatory arbitrage (Hogarth this issue).  
In parallel with this commercial growth, there has been an explosion in scholarly research on 
the ethical, legal and social implications (ELSI) of DTCGT. To give but one metric that indicates 
the scale of this research field, an early review of the ELSI landscape published in 2008 now has 
221 citations (Hogarth, Javitt and Melzer 2008). Like Myriad Genetics’ patents on the BRCA 1/2 
genes, DTCGT has become a lightning rod for broader concerns about the commercialisation of 
genetic testing (Caulfield et al. 2006). Why has the topic of DTCGT proved so popular? The 
relatively low cost of analysing the content of firm websites (Phillips and Saukko this issue) or 
media coverage of DTCGT (Hogarth and Saukko this issue) cannot be overlooked. The 
emergence of the second wave of DTCGT in 2006/7 came at a time when, it might be argued, 
ELSI researchers had begun to exhaust the possibilities of examining established paradigms of 
genetic testing: the domain of clinical genetics, the emerging market for pharmacogenomics, the 
first wave of genetic risk tests like BRCA for breast/ovarian cancer and APOE4 for Alzheimer’s. 
Each of these had been the subject of intensive scrutiny and DTCGT was seized upon with 
enthusiasm as fresh grist to the ELSI analytic mill. Although tackling a novel topic, this new 
wave of scholarship pursued many familiar research themes – geneticisation (e.g. Harris and 
Wyatt 2011), genetic subjectivities (e.g. Reardon 2011), informed consent (e.g. Hawkins and Ho 
2012), regulation and governance (e.g. Borry, Cornell and Howard 2011), and the promissory 
nature of personalised medicine (e.g. Tutton 2014).  
Looking at a number of these topics in turn, we identify some of the key issues and approaches 
of the ELSI literature on DTCGT and highlight the original contributions made by papers in this 
collection. To begin, we consider DTCGT’s struggle for legitimacy and its entanglement with 
regulatory authorities.  
Regulation 
As has become typical for emergent biotechnologies, the ethical, legal and social implications of 
genetic testing have been the subject of much academic research, policy deliberation and public 
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debate in the mass media over the last two decades, and much of this normative scrutiny has 
focused on the issue of regulation. Deliberation around how DTCGT might be regulated is thus 
just one dimension of a much broader debate about the governance of genetic testing that can 
be traced back to the early 1990s when newborn screening for monogenic disease was the topic 
of concern (see for instance, Nuffield Council on Bioethics 1993). The regulatory debate has 
periodically changed focus in response to technological innovations (most recently non-invasive 
prenatal testing and next-generation sequencing), new diagnostic modalities (such as 
companion diagnostics to identify patient sub-populations eligible for targeted cancer 
therapeutics) and changes in test delivery mechanisms (exemplified by DTCGT) (Hogarth 
forthcoming). Indeed, one might suggest that DTCGT combines all three drivers of regulatory 
debate: technological innovation, since second-wave firms relied both on advances in array-
based high throughput genotyping and the emergence of Web 2.0 technologies (see Saukko this 
issue); and new diagnostic modalities, in this case polygenic risk assessment, which the DTC 
firms pioneered; as well as obviously a change in test delivery models. Given this powerful 
convergence, it is perhaps unsurprising that DTCGT became a lightning rod for discussion of 
longstanding regulatory concerns. 
Concerns have been raised about whether it is appropriate to offer genetic testing without 
medical supervision; about the accuracy and utility of the tests being offered; and about the 
veracity of marketing claims made by firms. Whilst the first of these concerns is broadly 
applicable across much of the field of genetic testing - from well-established tests for single-
gene disorders to pharmacogenetic tests - the latter concern has been primarily focused on 
susceptibility tests for common diseases. In this respect, concern about DTCGT converged with 
more longstanding concerns about susceptibility testing that first emerged with the discovery of 
the link between the APOE gene and Alzheimer’s Disease in 1992. The discovery of the BRCA 
1/2 genes two years later, and subsequent rapid commercialisation of genetic risk assessment 
for breast and ovarian cancer in the USA, focused the regulatory debate onto predictive genetic 
testing. A series of policy reports were produced across the globe, highlighting concerns about 
the predictive value and clinical utility of genetic risk tests, and warning about the psycho-social 
harms that these new technologies might generate.  
Common policy recommendations emerging from this phase of policy deliberation included the 
need for informed decision-making, supported by appropriately qualified healthcare 
professionals (often encompassing genetic counselling), and the need to ensure rigorous, 
independent evaluation of tests before they enter routine clinical use. As the second wave of 
DTCGT was emerging in 2007/8, these recommendations were being enshrined in transnational 
standards generated by international bodies such as the Council of Europe’s 2008 Additional 
Protocol to the Convention on Human Rights and Biomedicine, concerning Genetic Testing for 
Health Purposes, and the Organisation for Economic Cooperation and Development’s 2007 Best 
Practice Guidelines for Quality Assurance in Molecular Genetic Testing (Ibaretta and Hogarth 
2010). The need for the involvement of a healthcare professional in genetic testing is also 
enshrined in legislation in a number of European countries such as France, Germany and 
Portugal (Borry et al. 2012). However, thus far it remains unclear how many states have 
implemented the standards they signed up to when developing the OECD guidelines, and in 
those European states with national legislation there is little evidence of enforcement of the 
regulations. 
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One branch of ELSI scholarship has sought to provide empirical evidence of the potential for 
consumer harm. As Philips notes in this issue, a recurrent theme has been the asymmetries of 
information between firm and consumer and the failure of firms to provide accurate and 
comprehensive information about their tests (see for instance, Geransar and Einsiedel 2008 and 
Hennen, Sauter and Van Den Cruyce 2010). A second strand of research has analysed the 
loopholes in existing regulatory regimes and proposed ways to address them to ensure pre-
market evaluation of new tests using medical device regulation, either through legislative 
reform or stricter enforcement of existing powers (see for instance, Hogarth, Javitt and Melzer, 
2008).   
However, when regulators have acted in the DTCGT market, their actions have proven 
controversial. The US Food and Drug Administration’s efforts to regulate DTCGT firms as 
manufacturers of medical devices have been characterised by some ELSI scholars as premature 
(Prainsack et al. 2011), unnecessary (Wright, Hall and Zimmern 2011), or even an infringement 
of constitutional rights (Farahany 2014). These regulatory sceptics question whether there is 
evidence of harm, and some suggested that further empirical research was needed to identify 
the impact of DTCGT on consumers. The subsequent research literature on consumer attitudes 
is addressed in the section on geneticisation below, but we note in passing that this research 
agenda, which sought to investigate the actual harms and benefits of DTCGT services, in 
particular genetic risk profiles, has put the evidentiary cart before the horse, interrogating 
questions of clinical utility in the absence of evidence of clinical validity (i.e. the accuracy of the 
risk assessments). Typical of the way that this latter concern is effaced in this literature is the 
argument advanced by Caulfield et al. (2013), who suggest that the lack of evidence that genetic 
risk testing causes psychological harm demonstrates that calls for enhanced regulation are an 
example of “ELSI hype”. This conclusion neglects longstanding scientific concerns that genetic 
susceptibility tests provide inaccurate and misleading risk scores. Janssens et al. (2008) 
reviewed meta-analyses of gene-disease associations relevant to DTGT risk tests and found 
“significant associations with disease risk for fewer than half of the 56 genes that are tested in 
commercially available genomic profiles” (595). 
Until two years ago the debate about the impact of using medical device regulation to govern 
DTCGT firms was largely conjectural, with much uncertainty about the scientific standards that 
might be applied or what types of tests regulators would allow firms to offer directly to 
consumers. Since 2015, the FDA has approved two regulatory submissions from 23andMe (the 
first for carrier testing and the second for genetic risk assessment), and a clearer picture of how 
regulation might shape this market is beginning to emerge. These developments occurred at the 
same time as this special issue took shape, and Curnutte’s paper provides the first ELSI analysis 
of the new regulatory paradigm. Curnutte characterises DTGT as a disruptive technology that 
challenged existing regulatory arrangements but which ultimately has been folded within the 
established regulatory regime. Curnutte describes how the FDA allowed 23andMe’s tests to be 
down-classified as Class II, medium risk devices, permitting them to use a less onerous 
regulatory pathway than Class III, high-risk devices, based on the firm’s ability to provide 
evidence on the analytic and clinical validity of the tests and to demonstrate consumer 
comprehension of test results. She concludes that the boundaries of this new regulatory 
paradigm are not yet clear; it remains to be seen, for instance, whether 23andMe will seek FDA 
approval for the pharmacogenetic tests it once offered (and continues to offer in other 
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jurisdictions). Moreover, as Hogarth (this issue) points out, the genetic risk tests that FDA have 
approved are all for single-gene risk markers which, although their clinical utility is questioned, 
are supported by a body of evidence that has established their predictive accuracy (i.e. clinical 
validity). The FDA has yet to approve a polygenic risk score of the type that was central to the 
product offer of firms like 23andMe and Navigenics, and over which much scientific doubt 
remains. Whether the FDA will approve such tests, and what evidentiary standard will be 
applied, remains to be seen. 
Like Curnutte, Hogarth is interested in the intersection of disruption and regulation, but for 
Hogarth disruption is an ideological construct and a commercial strategy, rather than a quality 
inherent in DTCGT services. Hogarth describes 23andMe’s strategic shift from regulatory 
arbitrage to a combination of regulatory compliance and political lobbying as the firm 
responded to the FDA’s decision to exercise its authority over the DTCGT market. In situating 
23andMe in the tradition of Silicon Valley disruptor firms, Hogarth provides a broader context 
for understanding the regulatory strategies of DTCGT firms. 
Approaching the governance question from a quite different perspective, Phillips shifts the 
focus away from medical device regulation and towards more generic consumer protection 
legislation. Issues of consumer comprehension, hitherto discussed in terms of genetic literacy, 
are recast as matters of legal expertise, as attention shifts from misleading product claims to 
confusing contract terms. Just as Hogarth’s paper demonstrates how 23andMe’s practice of 
regulatory arbitrage is a strategy generic to self-styled dotcom disruptor firms operating in 
many different consumer markets, so Phillips draws our attention to how DTCGT exemplifies 
the broader governance challenges of internet-based commerce. Her focus is the common 
recourse to clickwrap and browsewrap contracts that mitigate against consumer 
comprehension by dint of the complexity of their terms and their length (23andMe’s terms of 
service is 9,081 words, and its privacy statement is even longer at 15,807 words). Philips points 
to the UK Competition & Markets Authority (CMA) as the regulatory agency with the power to 
remedy these problems. What impact might this have? Drawing on a 2016 CMA report on unfair 
terms in cloud computing contracts, Philips provides a typology of terms commonly found in 
her sample of DTCGT contracts, that the CMA’s report suggested might be in breach of consumer 
legislation.  
Geneticisation: past and present 
A long-standing debate vis-a-vis DTCGT is the concern that such tests fuel 'geneticisation,' i.e. 
the idea that genes determine health and life processes.  In her classic article on women’s health 
and geneticisation Lippman (Lippman, 1991) argued that genes have become the ‘lens’ through 
which health is understood. So, low birth weight came to be seen as resulting from genes rather 
than poor nutrition and prenatal healthcare, illustrating how geneticisation is also frequently 
coupled with individualistic notions of health and illness, downplaying social and 
environmental causes and solutions. Deterministic metaphors for genes, such as ‘blueprint’ or 
‘book of life,’ analysed also on the pages of this journal (Nelkin, 1994; Nerlich & Hellsten, 2004) 
have proved enduring in popular and scientific media, even if new scientific approaches, such as 
epigenetics, have generated new metaphors, such as genes as musical scores that can be played 
differently (Stelmach & Nerlich, 2015). Analyses of the websites of DTC genetic testing 
companies have noted that they represent genes in deterministic fashion (Nordgren & Juengst, 
2009) and foster the neo-liberal notion of health as an individual responsibility (Harvey, 2010). 
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Saukko’s paper in this issue continues these conversations and compares the representation of 
genes on the websites and media coverage of the now defunct nutrigenetic testing company 
Sciona and the current personal genome service 23andMe. Sciona represented genes as coding 
for predisposition for disease, which could be offset by eating specific foods or micronutrients. 
23andMe represented genes in a new way, as digital big data to be browsed, uploaded and 
shared by consumers and companies online. On closer inspection, however, 23andMe continued 
to represent genes as coding for predisposition for disease to be mitigated by individual lifestyle 
change and targeted drugs, both in its genetic test results and the research it supported by 
selling its customers genetic and survey data to private companies. Yet, the metaphor of big 
data, which cast genes as digital big data to be circulated, shared, pooled and correlated by 
consumers and companies alike to produce new ‘discoveries’, was novel in social and economic 
terms, legitimising 23andMe’s business model of consumer genetics and private biobanking. 
The way in which 23andMe mobilises discourses of open access, sharing and participatory 
science to support selling its customers’ DNA for private gain has been noted by various 
scholars (Harris, Kelly, & Wyatt, 2016; Van Dijck & Poell, 2016). What Saukko’s article adds to 
this discussion is the observation that, regardless of its claims to be a ‘disruptive’ actor 
(Hogarth, this issue), 23andMe represented genes in conventional terms as coding for disease at 
the same time as adopting the metaphor of genes as digital data to be shared and traded online. 
Genetic determinism has also raised concerns about lay understanding, with some authors 
suggesting that predictive genetics might give consumers false reassurance or generate undue 
anxiety or even fatalism. In this respect studies on the effects of DTCGT on consumers have 
found the tests to have null effects (for a synthesis, see Saukko 2013): consumers in these 
surveys do not interpret DTCGT genetic tests deterministically (Kaphingst et al. 2012); they do 
not suffer long-term anxiety, but neither do they adopt healthier behaviours (Bloss, Schork, & 
Topol 2011; James et al. 2011). A qualitative study of early adopters in the USA found them to be 
interested in health but aware of the limitations of the tests (McGowan, Fishman, & Lambrix 
2010), and a study of Finnish consumers found them to be interested in genetics but also 
sceptical about the tests, or making sense of them through alternative interpretive frameworks, 
such as religion (Ruckenstein 2016). This survey data notwithstanding, anecdotal evidence 
points to the very profound impact that predictive genetics can have, as Messner’s (2011) 
account of patients who had undergone APOE4 testing for Alzheimer’s Disease demonstrates. 
Finley’s paper in this issue provides a similarly compelling anecdote of patient anxiety 
recounted by a UK clinician. 
The article by Finley in this issue explores attitudes towards DTCGT amongst UK consumers and 
clinicians working in the National Health Service (NHS). Clinicians have been amongst the most 
vocal critics of DTCGT, and Finley’s clinician interviewees were similarly sceptical, although 
they acknowledged that their fears that DTCGT consumers would take up NHS clinician time 
had not yet become a reality (perhaps unsurprising given the low rate of consumer uptake (see 
Hogarth this issue)). Some of the consumer interviewees, on the other hand, had bought into the 
notion of commercial personalised medicine, wanting to acquire personalised information 
about themselves, and portraying clinicians as “pretty stuck in the past”. Framing these views as 
a conflict between collective and personalised medicine, Finley locates this dichotomy in the 
contemporary politics of the NHS in a period of austerity economics.  
Promissory capitalism: the political economy of DTCGT 
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Attention to questions of political economy has been scant in the ELSI genomics literature, 
which, even when addressing matters of governance, has paid more attention to upstream 
research (in particular biobanking) than downstream commercialisation. Research on the 
DTCGT market is a rare exception to this rule, but even this body of work pays limited attention 
to how the firms in this emergent market seek to create and capture value. Paradoxically, 
although much of the ELSI interest in DTCGT is generated by the controversy around the 
commercialisation of genomics, it seems that there is limited interest in the commercial realities 
of DTCGT. 
Whether this expanding market is creating or destroying financial value is moot, and thus far 
the ancestry testing market seems the most successful in terms of known customer numbers. 
The market leader Ancestry DNA has more than 2 million customers, however the firm has 
integrated vertically with so many other firms in the genealogy market that its commercial 
worth is only partially tied to its genotyping service. Firms offering health-related testing have 
struggled to establish sustainable business models (see Hogarth this issue), a problem common 
to many emergent biotechnologies (Plagnol, Rowley, Martin and Livesey 2009). 
One approach to the economics of DTCGT has been to focus on the relationship between firm 
and consumer. Harris, Wyatt and Kelly (2013) draw on the concepts of clinical labour and free 
labour to understand how 23andMe seeks to derive financial value from the work that their 
customers perform as research participants. In this issue Hogarth offers a different approach, 
focusing on the relationship between venture capitalists and DTCGT firms. Examining 
23andMe’s status as a self-styled ‘disruptor’ firm, Hogarth explores issues of worth and value in 
the bioeconomy, and what Paul Martin (2015) has called “the promissory character of 
contemporary capitalism”. Situating 23andMe in its geographical setting of Silicon Valley, 
Hogarth describes how the firm is typical of the distinctive local culture of entrepreneurialism 
that has developed in the area since the 1980s. Hogarth suggests that in Silicon Valley the 
relationship between moral worth and economic value is mediated through the concept of 
disruptive innovation, which functions as both ideological construct and a set of commercial 
practices utilised by the founders of start-up firms and the venture capitalists (VC) who invest 
in them. Drawing attention to 23andMe’s success in attracting the support of VC investors, he 
points to the recent massive increase in private capital available for start-ups in Silicon Valley 
and describes the controversy the new era of ‘unicorn’ firms has created: the crisis of corporate 
governance that surrounds disruptor firms like Theranos and Uber, and the warnings many 
experts are now raising that the growth in unicorn firms signals a new high-tech investment 
bubble. 
And beyond? 
Taken together, the papers in this special issue identify some key trends and developments that 
may shape the future of DTCGT. In the USA, the FDA is pushing the DTCGT sector toward more 
validated tests and asserting greater control over consumer information and test accuracy. To 
the extent that regulation may now be acting as a barrier to market entry, it is likely that 
23andMe has gained a major competitive advantage in being the only FDA-approved DTCGT 
firm, a significant development given the firm’s ambitions for market dominance. 
Aside from the changing regulatory environment, there are other important contextual shifts. 
Firstly, much of the hype in consumer diagnostics has shifted from genomics to mobile digital 
health (mHealth) technologies. As with DTCGT, the issue of technology validation has been 
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raised, with the US Federal Trade Commission recently sanctioning one health app developer 
for making unsubstantiated medical claims and stating that the device must be tested in a 
Randomised Control Trial (Wicklund 2016). However, as with DTCGT, there is uncertainty 
about the applicability of the established regulatory paradigm for medical devices to this new 
generation of technologies that straddle the space between the consumer market for 
wellness/lifestyle products and the clinical market for medical devices.  
As Saukko’s paper indicates, the integration of genomics into this new technology paradigm of 
mHealth is predicted, not least by 23andMe, but at the moment most mHealth applications are 
focused on other types of biomarker, which suggests that geneticisation of healthcare remains a 
partial and contested process that both competes with, and is dependent on, convergence with 
other socio-technical trajectories. As personalised medicine has been rebranded as precision 
medicine, there is growing acceptance that other types of ‘omics markers may be more clinically 
useful than germline DNA, and that the utility of genomic markers may be enhanced by 
integration with other biomarkers (Anonymous 2012). 
How DTCGT firms will fare in this changing socio-technical landscape remains to be seen. 
Consumer surveys have shed light on the attitudes of early adopters, but the attitudes of the lay 
public can be clearly read from the sales figures: given the very low uptake of DTCGT, the 
prevailing attitude amongst the general public is at best indifference. Whether FDA approval 
provides a form of reassurance that can quicken the pace of consumer uptake also remains to be 
seen. Given the slow progress of the broader project of personalised/precision medicine (Green 
and Guyer 2011), it is perhaps unsurprising that DTCGT firms have yet to realise their vision of 
a mass market for genomic knowledge .  
However, even amongst those sceptics who believe that the business models of DTCGT firms are 
as shaky as their scientific claims, there can be little doubt that the second wave of firms has 
enjoyed one notable success: they have been able to shift the discursive terrain on which the 
future of genomics is contested. In the face of a variety of regulatory efforts, and in defiance of a 
decade of policy angst about the potential harms of predictive genetics, they have persuaded 
many that genomic knowledge is fascinating rather than scary; and they have asserted the 
principle that individuals have a right to their genome. It is an indication of the power of this 
principle that the FDA has been at pains to publicly state that they do not wish to contest it (see 
both Saukko and Curnutte in their contributions to this issue). As Hogarth’s paper suggests, the 
future of DTCGT may hinge as much on winning the ideological battle and the ability of firms to 
generate compelling visions of social transformation, as it does on technological advances or 
managerial competence. In this respect the growth of the mHealth market represents not simply 
an opportunity for new forms of technology convergence and commercial synergy, but the 
emergence of new allies in the ideological struggle to advance the cause of routine consumer 
health monitoring as a new individualised form of preventive medicine. However, the 
commercial push has been met with increasing professional critique: the Choosing Wisely 
campaigns and the international Preventing Overdiagnosis conference series, now in its fifth 
year, exemplify increasingly vocal and organised scepticism about screening/early disease 
detection as a public health goal. If DTCGT remains a market in the making, then the future 
progress of DTCGT will in part be determined by the contest between these two contrasting 
visions. 
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